"10.1371_journal.pone.0077398","plos one","2013-10-15T00:00:00Z","Ming Li; Jianpeng Gao; Runhua Feng; Yuling Wang; Xuehua Chen; Jianyu Sun; Dongqing Zhang; Zhenggang Zhu; Lee M Ellis; Mason Lu; Jeffrey E Lee; Zhenqing Feng; Bingya Liu","Department of Pathology, Nanjing Medical University, Nanjing, Jiangsu Province, China; Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijing Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China; Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America; Shanghai MabStar, Inc., Shanghai, China; Shanghai Institute of Immunology, Shanghai Jiaotong University School of Medicine, Shanghai, China","Conceived and designed the experiments: M. Li JG DZ LME M. Lu JEL ZZ ZF BL. Performed the experiments: M. Li JG RF XC YW JS M. Lu. Analyzed the data: M. Li JG M. Lu. Contributed reagents/materials/analysis tools: M. Li JG DZ LME M. Lu JEL ZZ ZF BL. Wrote the manuscript: M. Li JG M. Lu JEL BL ZF.","All authors are inventors of a pending patent application regarding the immunizing mice, preparing MS17-57 hybridoma and use of MS17-57 monoclonal antibody for cancer treatment. The authors declare that two authors were employed by a commercial company, Shanghai MabStar, Inc. The authors also declare that MS17-57 as well as the screening method has been submitted for patent application with the title of “Generation of anti-ectopically expressed alkaline phosphatase mAb, its method and applications” (a pending patent), State Intellectual Property Office of the People’s Republic of China (CN201310090565.9). This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials. The other four mAbs will be patented and the results will be published as well.","2013","10","Ming Li","ML",13,TRUE,1,1,1,1,TRUE,TRUE,TRUE,10,"2;3;4;5;6;7;8;11;12;13",TRUE
